This matched-controlled study assessed the safety of estrogen replacement therapy (ERT) in breast cancer survivors by comparing 56 women who received ERT to matched controls based on age at diagnosis, stage of disease, and year of diagnosis. With a median follow-up of 12.8 years and a median ERT duration of
